Several investigators have shown that CpG-DNA has outstanding effects as a Th1-responsive adjuvant and that its potent adjuvant effects are enhanced by encapsulation with a liposome of proper composition. In this study, we showed that encapsulation with phosphatidyl-β-oleoyl-γ-palmitoyl ethanolamine ( 
INTRODUCTION
TLR9 in the innate immune system recognizes bacterial DNA and synthetic oligodeoxynucleotides that contain unmethylated CpG dinucleotides in the context of particular base sequences (CpG-DNA) as being non-self (1) . CpG-DNA can be employed for regulation of the immune system, including stimulation of B cell proliferation, production of antibodies, and stimulation of macrophages, dendritic cells, and natural killer cells (2) (3) (4) . Several investigators have shown that the CpG-DNA has an outstanding immunostimulatory activity for inducing a strong Th1 immune response, resulting in induction of Th1 cytokines such as IL-12, IFN-α and IFN-γ (3) (4) (5) . The enhanced Th1 responses contribute to the protection of the host from infectious agents (6) . CpG-DNA also improves antigenpresenting cell activity through upregulation of major histocompatibility (MHC) class II molecules and costimulatory molecules (CD40, CD80, and CD86) (7) (8) (9) . Consequently, CpG-DNA has been widely applied as an effective vaccine adjuvant for infectious diseases and cancer (8, 9) . CpG-DNA can be divided into 2 classes based on the backbone type. First, the phosphrothioate backbone-modified CpG-DNA (PS ODN) includes the oligodeoxynucleotides stabilized by sulfurs replaced on the nonbridging oxygen atoms in the backbone. Although PS-ODN is able to dramatically enhance the CpG-DNA-induced immune responses by resistance to nuclease activity and improved the efficiency of CpG-DNA uptake into cells, it was reported that PS-ODN provokes severe side effects in a CG sequence-dependent and backbone modification-dependent manner (10) (11) (12) . Second, the natural phosphodiester bond CpG-DNA (PO-ODN) is a regulator of the immune response and an immunoadjuvant for the induction of Ag-driven Th1 responses without severe side effects. However, the PO-ODN is susceptible to nuclease activity, and the immunostimulatory activity of PO-ODN is relatively lower than that of PS-ODN (4). Previously, we developed potent immunomodulatory PO-ODN from chromosomal DNA sequences of M. bovis and E. coli (15, 16) . The PO-ODN, specifically MB-ODN 4531(O) containing immunomodulatory CpG motifs, regulates expression of Th1 cytokines and does not have severe side effects. We also found that the PO-ODN encapsulated in a phosphatidyl-β-oleoyl-γ-palmitoyl ethanolamine (DOPE): cholesterol hemisuccinate (CHEMS) complex (Lipoplex(O)) is able to enhance the stimulation of immune responses in the cells of humans and mice (15) . Here, we investigated the effects of liposome-encapsulated PO-ODN or PS-ODN on TLR9-mediated signal transduction pathways and performed screening of B cell epitopes using several peptides and Lipoplex(O).
RESULTS AND DISCUSSION

Effect of PS-ODN encapsulated in liposomes on IL-8 promoter activation
Although investigators developed the natural PO-ODN to http://bmbreports.org overcome severe side effects of PS-ODN, the immunostimulatory activities of PO-ODN in human cells are limited (16, 17) . To enhance the immunostimulatory activity of PO-ODN, several liposomes were applied as a vehicle for delivery. When PO-ODN was encapsulated in DOTAP, the uptake of PO-ODN and the production of IFN-α were enhanced in hPBMCs (18, 19) . Previously, we screened a natural immunostimulatory PO-ODN from bacterial chromosomal DNA, but the PO-ODN was much less potent in inducing HLA-DRA and hBD-2 promoter activation in RPMI 8226 cells than in mice (13, 14, 20) . However, PO-ODN encapsulated in DOTAP can elicit HLA-DRA and hBD-2 promoter activation and gene expression in RPMI 8226 cells in a CG sequence-dependent manner (20) . We also compared the effects of liposome-encapsulated PO-ODN on the IL-8 promoter activation and cytokine production in mouse cells and human cells (15) . After stimulation with PO-ODN encapsulated in liposomes such as DOTAP, the DOPE : CHEMS complex, and the DSPC : CHEMS : PEG-PE complex, the IL-8 promoter was significantly activated in both human cells and mouse cells. The most potent activation was produced by PO-ODN encapsulated in DOPE : CHEMS (1 : 1 ratio) complex. We refer to MB-ODN 4531(O) encapsulated in a DOPE : CHEMS) complex as Lipoplex(O). Lipoplex(O) induced the production of cytokines such as IL-6, IL-12, and IFN-γ in mouse splenocytes and hPBMCs, and also induced secretion of IL-12 and IFN-γ for much longer time periods than MB-ODN 4531(O) did by in vivo application, in a TLR9-dependent manner (15) . In this study, we determined the effects of liposome-encapsulated MB-ODN 4531(S) (PS-ODN) on IL-8 promoter activity in a human B cell line (RPMI 8226) and the mouse macrophage cell line, RAW 264.7. The MB-ODN 4531(S) encapsulated in a DOPE : CHEMS complex (Lipoplex(S)) was more effective in eliciting IL-8 promoter activation than free MB-ODN 4531(S) in the human B cell line (Fig. 1A) . In agreement with the results from PO-ODN, PS-ODN encapsulated in DOPE : CHEMS (1 : 1 ratio) complex produced the largest improvement of IL-8 promoter activation in human and mouse cells (Fig. 1B) . Furthermore, Lipoplex(S) more potently activated the IL-8 promoter in human RPMI 8226 cells than did MB-ODN 4531(S) encapsulated in other liposomes such as DOTAP, lipofectamine, or 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine (DSPC) : CHEMS : phosphatidylethanolamine-poly(ethylene glycol) (PEG-PE) (6 : 4 : 0.3 ratio) complex. To investigate the contribution of CG dinucleotide sequences to the ability of Lipoplex(S) to activate IL-8 promoter, we synthesized MB-ODN 4531GC(S) in which one CG dinucleotide sequence was reversed to GC. When the cells were treated with MB-ODN 4531GC(S) encapsulated in a DOPE : CHEMS complex, and the IL-8 promoter activation was significantly reduced, but still observed in the mouse and human cell lines (Fig. 1B) , showing the strong immunostimulatory effect of the phosphorothiate modification. Taken together, encapsulation with DOPE : CHEMS (1 : 1 ratio) complex greatly enhanced the immunostimulatory activity of CpG-DNA in human cell lines in a backbone modification-independent manner.
Enhanced interaction of CpG-DNA and TLR9 by encapsulation in a DOPE : CHEMS complex
Previously, we have shown that the Lipoplex(O) can elicit en-http://bmbreports.org BMB reports hanced intracellular uptake, endosomal localization, and biological activity of CpG-DNA (15) . As CpG-DNA-mediated immune activation was initiated by recognition of TLR9 (1), we decided to evaluate the effects of DOPE : CHEMS complex encapsulation on binding of CpG-DNA to TLR9 and established HEK 293 cells stably expressing TLR9. After the cells were incubated with biotin-labeled MB-ODN 4531(O) or MB-ODN 4531(S) for 1 h, immunoprecipitation assays were performed for identification of the TLR9 and CpG-DNA interaction using strepavidin-conjugated beads in the cell lysates (Fig. 2) . 
Effects of CpG-DNA encapsulated in a DOPE : CHEMS complex on MyD88-and NF-κB-mediated IL-8 promoter activation
It was well-known that myeloid differentiation protein (MyD88) is engaged in TLR9-mediated intracellular signaling. Interaction of TLR9 with CpG-DNA induces activation of the MyD88/IL-1R-associated kinase (IRAK) pathway, leading to nuclear localization of several transcription factors such as NF-κB for cytokine gene expression (7). Therefore, we used an expression plasmid that encodes a dominant negative version of MyD88 (△MyD88) and a mutant IκBα protein (IκBα Super Repressor, IκBαSR) which cannot be phosphorylated on serines 32 and 36 to investigate the involvement of MyD88 and NF-κB activation in Lipoplex(O)-or Lipoplex(S)-induced IL-8 http://bmbreports.org promoter activation (Fig. 3A and 3B ). Cotransfection of △MyD88 or IκBαSR with the promoter-reporter construct markedly inhibited the IL-8 promoter activation in RPMI 8226 cells treated with Lipoplex(O) or Lipoplex(S). Furthermore, IL-8 promoter activation after stimulation with Lipoplex(O) or Lipoplex(S) was markedly decreased by the pretreatment with an IKK-2 inhibitor BMS-345541 or an NF-κB inhibitor PDTC ( Fig. 3C and 3D ). Based on these results, it is evident that typical MyD88-dependent NF-κB activation is also required for IL-8 promoter activation by CpG-DNA encapsulated in a DOPE : CHEMS complex in human cell lines in a backbone modification-independent manner.
IgG production by peptide epitope and CpG-DNA encapsulated in DOPE : CHEMS complex
Previously, we have shown the potent adjuvant effect of Lipoplex(O) on production of antibodies specific to B cell epitopes without carriers (15) . Specifically, we successfully produced antibody against human hepatocellular carcinoma-specific transmembrane 4 superfamily member 5 (TM4SF5) protein by immunization with a complex of synthetic peptide and Lipoplex(O) without carriers. Therefore, we used this system for screening of B cell epitopes against proteins of infectious pathogens. Specifically, we aimed to screen B cell epitopes originating from envelope protein (E protein) of hepatitis C virus (HCV-E), attachment glycoprotein G and fusion protein F of the human respiratory syncytial virus (HRSV-G and HRSV-F). Candidate peptide sequences of pathogen were selected and synthesized on the basis of their hydrophilicity, hydrophobicity, secondary structure, antigenicity index, and amphipathicity.
We screened B cell epitopes of HCV E protein, HRSV G protein, and F protein by immunizing BALB/c mice with each peptide and Lipoplex(O). As a result, the mice showed a dramatic increase in the production of HCV-E2 202 peptide-specific IgG (Fig. 4A-C) and HRSV-G1 peptide-specific IgG ( Fig. 4E and F) . The production of IgG was significantly higher when the peptides and CpG-DNA were coencapsulated with DOPE : CHEMS complex than with other liposomes, indicating the prominent adjuvant activity of Lipoplex(O) (Fig. 4D) . We also found that the complex of peptide and Lipoplex(O) induced significantly higher levels of IgG2a than IgG1, indicating a predominant Th1 response. Taken together, these results confirm that Lipoplex(O) can be used as a universal adjuvant for peptide-based B cell epitope screening and antibody production through enhanced TLR9 binding and MyD88-and NF-κB-mediated signal transduction. It also obviates the need for other adjuvants and carriers in production of antibody against peptide antigen. Our novel strategy using Lipoplex(O) might be extremely helpful for future applications in viral infectious diseases or cancers.
MATERIALS AND METHODS
ODNs and reagents
ODNs were synthesized by ST Pharm Co., Ltd (Seoul, Korea). The CpG-DNA sequences used in this study were either phosphodiester (O) or phosphorothioate-modified (S) versions of MB-ODN 4531 (14) . The expression vectors for mutant IκBα protein (IκBαSR) and the mutant of MyD88 (△MyD88) were kindly provided by Dr. Harikrishna Nakshatri (Indiana University, USA) and Dr. Jurg Tschopp (University of Lausanne, Switzerland), respectively. When necessary, the cells were preincubated with BMS-345541 (50 μM) or pyrrolidine dithiocarbamate (PDTC, 200 μM) for 1 h before stimulation with CpG-DNA or liposome-encapsulated CpG-DNA.
Cell culture
The human B cell line RPMI 8226 and mouse macrophage cell line RAW 264.7 were maintained in RPMI 1640 medium containing 10% FBS (Hyclone, Logan, UT, USA), 100 U/ml of penicillin and 100 μg/ml of streptomycin. Viability was assayed by trypan blue dye exclusion.
Preparation of CpG-DNA co-encapsulated in liposome complexes
Liposome complexes consisting of CpG-DNA co-encapsulated with several liposome formulations were prepared as previously reported (15) . Peptide and CpG-DNA co-encapsulated in liposome complexes were also prepared as previously described (15) .
Transfection and luciferase assays
Transfection and luciferase assays were performed as previously described (15) . Construction of recombinant human TLR9 expression vector and establishment of stable cell lines hTLR9 cDNA was amplified from RPMI8226 cells by a reverse-transcription polymerase chain reaction (RT-PCR) using the following primer sets: 5' primer, 5'-CTAGCTAGCATGGG-TTTCTGCCGCAG-3'; 3' primer, 5'-GGATCCCTATTCGGCCG-TGGGTCCC-3'. The amplified PCR products were cloned into pGEM-T easy vector (Promega, Madison, WI, USA) and then subcloned into the mammalian expression vector pcDNA-3.1/ Myc-His(-)B (Invitrogen, Carlsbad, CA, USA) using the restriction enzyme sites NheI and BamHI. For generation of hTLR9 stable cell lines, HEK293 cells were transfected with FuGENE 6 Transfection Reagent (Roche), after which the cells were selected in the presence of 500 μg/ml of G418 for 14 days. G418-resistant clones were selected and assayed for hTLR9 expression by immunoblotting with monoclonal antibody against hTLR9 (Cell Signaling Technology, Beverly, MA, USA).
Immunoprecipitation and immunoblotting
HEK 293 cells stably expressing hTLR9 were treated with 5 μg/ml of biotin-labeled CpG-DNA or biotin-labeled CpG-DNA encapsulated in DOPE : CHEMS (1 : 1 ratio) complex. After 30 min, the cells were harvested and cell lysates were incubated for 2 h at 4 o C in a streptavidin-conjugated Protein A-Sepharose CL-4B (10% (v/v)) slurry (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Immunocomplexes collected by centrifugation were subjected to SDS-PAGE and Western blot analysis using anti-TLR9 antibody.
Selection and synthesis of B cell epitope peptides
The candidate epitope peptides of the HCV E protein (HCV-E1 57, ) were selected as previously described (15) . The peptides were synthesized using an automated peptide synthesizer (Peptron III-R24, Peptron, Daejeon, Korea).
Mice and immunization
Mice were maintained under specific-pathogen-free conditions. We purchased 4-week-old male BALB/c (H-2 b ) mice from Central Lab. Animal, Inc. (Seoul, Korea). Our animal studies were approved by the Institutional Animal Care and Use Committee of Hallym University (Hallym 2009-47). On three occasions at 10 day intervals, the mice were injected intraperitoneally (i.p.) with 50 μg of peptides (50 μg) supplemented with either 50 μg of CpG-DNA or CpG-DNA encapsulated in liposomes.
Antigen-specific Ig ELISA assay
Mouse sera were obtained by orbital bleeding before each injection as well as by sacrifice 10 days after final injection. To measure the amounts and titers of total IgG, IgG1, and IgG2a, 96-well immunoplates were coated with 5 μg/ml of each peptide and then blocked with 0.05% of Tween-20 in PBS (PBST) containing 1% BSA. Total IgG, IgG1, and IgG2a levels were measured as previously described (15) .
